Answers are grounded in this paper and cite their sources.
Triple-negative breast cancer (TNBC) exhibits marked spatial heterogeneity and variable sensitivity to immune checkpoint blockade, creating a need for whole-body biomarkers of immune-relevant tumor states. Here, tumor-cell EphA2 is identified as implicated in an immune-restricted TNBC phenotype. Human transcriptomic and spatial analyses, together with immunocompetent tumor models, show that EphA2 is associated with aggressive malignant-cell states, reduced CD8 + T-cell infiltration and effector function, and limited responsiveness to PD-1 blockade. Mechanistic analyses linked EphA2 to a CD73-related AMP-to-adenosine program accompanied by coordinated changes in AKT/mTOR–HIF-1α signaling, whereas CD73 re-expression attenuated several tumor and immune phenotypes associated with Epha2 knockdown. Guided by this biology, two gallium-68-labeled EphA2-targeting bicyclic peptide radiotracers are compared through AI-assisted computational evaluation and experimental validation. The FZEAR11 precursor showed stronger measured EphA2 affinity than FZEAR12, while [ 68 Ga]Ga-FZEAR11 exhibited higher cellular and tumor uptake, rapid blood clearance, and superior tumor-to-muscle contrast relative to [ 68 Ga]Ga-FZEAR12. Blocking studies and EphA2-high versus EphA2-low models support a substantial target-associated and saturable component of tumor accumulation. Exploratory first-in-human PET/CT in three patients demonstrates same-day visualization of pathologically confirmed, EphA2-expressing TNBC lesions against a low soft-tissue background. These findings establish a mechanism-informed strategy for EphA2 PET and support further evaluation of [ 68 Ga]Ga-FZEAR11 for whole-body target assessment in TNBC.
No takes yet. Share an insight, caveat, or question.
Bian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: